A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome by Xin Xu et al.
ORIGINAL RESEARCH ARTICLE
published: 07 March 2014
doi: 10.3389/fncel.2014.00068
A selective histone deacetylase-6 inhibitor improves BDNF
trafficking in hippocampal neurons from Mecp2 knockout
mice: implications for Rett syndrome
Xin Xu1, Alan P. Kozikowski2 and Lucas Pozzo-Miller1*
1 Department of Neurobiology, Civitan International Research Center, The University of Alabama at Birmingham, Birmingham, AL, USA
2 Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL, USA
Edited by:









Lucas Pozzo-Miller, Department of
Neurobiology, The University of
Alabama at Birmingham, SHEL-1002,
1825 University Blvd., Birmingham,
AL 35294-2182, USA
e-mail: lucaspm@uab.edu
Rett syndrome (RTT) is a neurodevelopmental disorder caused by loss-of-function
mutations in the transcriptional modulator methyl-CpG-binding protein 2 (MECP2). One
of the most prominent gene targets of MeCP2 is brain-derived neurotrophic factor (Bdnf ),
a potent modulator of activity-dependent synaptic development, function and plasticity.
Dysfunctional BDNF signaling has been demonstrated in several pathophysiological
mechanisms of RTT disease progression. To evaluate whether the dynamics of BDNF
trafficking is affected by Mecp2 deletion, we analyzed movements of BDNF tagged
with yellow fluorescent protein (YFP) in cultured hippocampal neurons by time-lapse
fluorescence imaging. We found that both anterograde and retrograde vesicular trafficking
of BDNF-YFP are significantly impaired in Mecp2 knockout hippocampal neurons.
Selective inhibitors of histone deacetylase 6 (HDAC6) show neuroprotective effects in
neurodegenerative diseases and stimulate microtubule-dependent vesicular trafficking
of BDNF-containing dense core vesicles. Here, we show that the selective HDAC6
inhibitor Tubastatin-A increased the velocity of BDNF-YFP vesicles in Mecp2 knockout
neurons in both directions by increasing α–tubulin acetylation. Tubastatin-A also restored
activity-dependent BDNF release from Mecp2 knockout neurons to levels comparable
to those shown by wildtype neurons. These findings demonstrate that a selective
HDAC6 inhibitor is a potential pharmacological strategy to reverse cellular and synaptic
impairments in RTT resulting from impaired BDNF signaling.
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INTRODUCTION
Rett syndrome (RTT), an X-linked postnatal neurodevelopmen-
tal disorder associated with intellectual disabilities, is primarily
caused by mutations in methyl-CpG-binding protein 2 (MECP2),
the gene encodingMeCP2, a transcriptional modulator that binds
to methylated CpG sites in promoter regions of DNA (Nan et al.,
1997; Amir et al., 1999; Percy and Lane, 2005). A number of
genes including brain-derived neurotrophic factor (Bdnf ) were
identified to be regulated by MeCP2 and relevant to the patho-
genesis of RTT (Bievenu and Chelly, 2006; Chahrour and Zoghbi,
2007). MeCP2 binds to the Bdnf promoter and directly mod-
ulates Bdnf expression in an activity-dependent manner (Chen
et al., 2003; Martinowich et al., 2003; Zhou et al., 2006). Several
studies have reported lower BDNF mRNA and protein levels in
various brain regions of Mecp2 deficient mice and RTT individ-
uals (Chang et al., 2006; Wang et al., 2006; Ogier et al., 2007; Li
et al., 2012). Reduced overall neuronal activity caused by MeCP2
deficiency is thought to contribute to BDNF downregulation.
Conditional Bdnf mutant mice showed similar RTT phenotypes
as Mecp2 knockout mice, while Bdnf overexpression rescued
some of the functional deficits observed in Mecp2 mutants and
extended their lifespan (Chang et al., 2006; Chahrour and Zoghbi,
2007). These findings strongly indicate BDNF plays a critical role
in neurological dysfunctions in RTT.
Prior to RTT, BDNF had been implicated in other neuro-
logical disorders due to its widespread function in neuronal
development, plasticity, differentiation, and survival (Poo, 2001;
Fahnestock et al., 2002; Gines et al., 2010; Hartmann et al.,
2012). Common among these BDNF-related disorders, such as
Alzheimer’s disease (AD), Huntington disease (HD), is the irreg-
ular trafficking of dense-core vesicles containing BDNF, as well
as activity-dependent BDNF release from those vesicles (Gauthier
et al., 2004; Chapleau et al., 2009; Poon et al., 2011). Intriguingly,
the single nucleotide polymorphism Val66Met observed in the
human BDNF gene resulted in more severe RTT symptoms and
an increased risk of seizure onset, suggesting that in addition to
BDNF expression levels, BDNF trafficking and release are altered
in RTT (Zeev et al., 2009; Hartmann et al., 2012). Live BDNF-
YFP imaging in cultured neurons offers the ability to investigate
dynamic trafficking of BDNF, which was reported to be identical
to that of endogenous BDNF in terms of its cellular localization,
processing and secretion (Haubensak et al., 1998; Kohara et al.,
2001; Lessmann and Brigadski, 2009; Hartmann et al., 2012).
Here, we report that vesicular trafficking of BDNF, as well as
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its activity-dependent release are significantly impaired in hip-
pocampal neurons of Mecp2 knockout mice, providing further
support for the role of BDNF signaling in RTT pathophysiology.
Histone deacetylase-6 (HDAC6), a member of the class II his-
tone deacetylases, is a unique cytosolic enzyme that regulates cell
motility (Hubbert et al., 2002; Matsuyama et al., 2002; Zhang
et al., 2003; Tran et al., 2007), endocytosis (Gao et al., 2007),
vesicle transport (Dompierre et al., 2007), cell migration and
degradation of misfolded proteins (Iwata et al., 2005; Valenzuela-
Fernandez et al., 2008) and other cellular process by deacetylating
α-tubulin, Hsp90 and cortactin (Fukada et al., 2012). HDAC6 has
emerged as an attractive target for pharmacological intervention
in several CNS diseases. Selective inhibition of HDAC6 is thought
to promote neuronal survival and regrowth after injury, offer-
ing a potential therapy for various neurodegenerative diseases
(Kazantsev and Thompson, 2008; Rivieccio et al., 2009; Butler
et al., 2010). For example, the non-selective HDAC inhibitor
trichostatin A (TSA) improves microtubule (MT)-dependent
transport of BDNF-GFP in cultured neurons expressing mutant
Huntingtin; this effect was ascribed to increased α–tubulin acety-
lation through the inhibition of cytoplasmic HDAC6 (Dompierre
et al., 2007). Indeed, Tubastatin-A (TBA), a more selective
HDAC6 inhibitor, showed neuroprotective effects in a model
of oxidative stress, and exhibited no toxicity compared to TSA
(Butler et al., 2010). Furthermore, TBA rescued the impairment
of mitochondrial transport in axons and mitochondrial elonga-
tion caused by Aβ exposure (Kim et al., 2012).We report that TBA
improves BDNF-YFP trafficking and activity-dependent release
inMecp2 knockout hippocampal neurons to reach wildtype levels,
suggesting that HDAC6 is a potential therapeutic target to restore
BDNF-dependent neurological function in the absence of func-




Breeding pairs of mice lacking exon 3 of the X chromosome-
linked Mecp2 gene (B6.Cg-Mecp2tm1.1Jae, “Jaenisch” strain in
a pure C57BL/6 background) (Chen et al., 2001) were pur-
chased from the Mutant Mouse Regional Resource Center at the
University of California, Davis. A colony was established at The
University of Alabama at Birmingham (UAB) by mating wildtype
males with heterozygousMecp2tm1.1Jae mutant females, as recom-
mended by the supplier. Genotyping was performed by PCR of
DNA sample from tail clips. Hemizygous Mecp2tm1.1Jae mutant
males are healthy until 5–6 weeks of age, when they exhibit RTT-
like motor symptoms, such as hypoactivity, hind limb clasping,
and reflex impairments (Chen et al., 2001). Animals were han-
dled and housed according to the Committee on Laboratory
Animal Resources of the National Institutes of Health. All exper-
imental protocols were annually reviewed and approved by the
Institutional Animals Care and Use Committee of UAB.
PRIMARY CULTURES OF HIPPOCAMPAL NEURONS AND
TRANSFECTION
Both hippocampi were dissected from anesthetized postnatal day
0 or 1 (P0-1)maleMecp2 knockoutmice and wildtype littermates,
and dissociated in papain (20U/ml) plus DNAse I (Worthington,
Lakewood, NJ) for 20-30min at 37◦C, as described (Amaral and
Pozzo-Miller, 2007). The tissue was then triturated to obtain a
single-cell suspension, and the cells were plated at a density of
50,000 cells/cm2 on 12mm poly-L-lysine/laminin coated glass
coverslips, and immersed in Neurobasal medium supplemented
with 2% B27 and 0.5mM glutamine (Life Technologies, Carlsbad,
CA). Neurons were grown in 37◦C, 5%CO2, 90% relative humid-
ity incubators (Thermo-Forma), with half of the fresh medium
changed every 3-4 days. After 11 days in vitro (DIV), neurons
were transfected with cDNA encoding BDNF-YFP (a gift from
M. Kojima) using Lipofectamine 2000 (Life Technologies) (0.8μg
DNA) according to the manufacturer’s protocol.
IMMUNOCYTOCHEMISTRY
All experiments were performed at 12-14DIV. For localiza-
tion of endogenous native BDNF, neurons were fixed with
4% (wt/vol) paraformaldehyde/sucrose in phosphate buffer (PB;
23mM NaH2PO4, 2mM Na2HPO4 pH 7.4) for 10min, and
incubated in 0.25% (vol/vol) Triton X-100 for 10min, then
washed with PB saline (PBS). After blocking with 10% (vol/vol)
goat serum in PBS, cells were incubated with anti-BDNF anti-
body (2μg/ml, Santa Cruz Biotechnology #SC-546) overnight at
4◦C, rinsed in PBS, and incubated with Alexa Fluor-488 sec-
ondary antibody (Life Technologies) for 1 h; coverslips were
then mounted with Vectashield (Vector Laboratories). Images
were acquired in a laser-scanning confocal microscope using a
solid-state 488 nm laser for excitation, and a 60X 1.4NA oil
immersion lens, and standard FITC dichroic and emission filters
(FluoView-300, Olympus; Center Valley, PA). For dual immuno-
cytochemistry, BDNF-YFP-expressing neurons were fixed with
3% formaldehyde in PB at 0◦C for 20min, permeabilized for
10min at room temperature with 3% formaldehyde containing
0.25% Triton X-100, and blocked with 10% bovine serum albu-
min (BSA) for 1 h at 37◦C. Primary goat anti-chromogranin B
(1:100; Santa Cruz) and rabbit anti-BDNF (1:100, Santa Cruz)
antibodies, as well as fluorescently-conjugated anti-goat and anti-
rabbit secondary antibodies (Molecular Probes) were diluted
in 1X PBS and 3% horse serum. Coverslips were mounted
with Vectashield (Vector Laboratories), and fluorescence images
were acquired with a cooled CCD camera (CoolSnap HQ2,
Photometics) on a wide-field fluorescence microscope (Eclipse
TE2000-U, Nikon Instruments); BDNF-YFP was imaged with
a standard FITC filter, and fluorescently-conjugated secondary
antibodies with standard FITC and TRITC filters. Images were
deconvolved using Metamorph (Molecular Devices).
TIME-LAPSE FLUORESCENCE IMAGING
Time-lapse imaging was performed 24–48 h after BDNF-
YFP transfection. For mitochondria trafficking, neurons were
incubated for 15min with MitoTracker Red (200 nM; Life
Technologies) prior to live imaging. Individual coverslips with
cultured neurons were transferred to a recording chamber
mounted on a fixed-stage upright microscope (Leica DM-
LFS with either a 63 × 0.9NA or a Zeiss 63 × 1.0NA water-
immersion objective), and continuously perfused (1ml/min)
with HEPES buffered artificial CSF (aCSF) at 32–34◦C,
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containing (mM): 119NaCl, 5 KCl, 2 CaCl2, 1.3MgCl2, 10 glu-
cose, 10 HEPES (pH 7.4). YFP was excited with 490± 12 nm light
using a galvanometric monochromator (Polychrome-II, TILL
Photonics; Germany), and its emission (>510 nm, FITC-LP cube)
was filtered and detected with an electron-multiplying cooled
CCD camera operating in frame-transfer mode (QuantEM:
512SC, Photometrics, Tucson AZ). MitoTracker Red was excited
with 560 ± 12 nm and imaged through a standard TRITC cube.
Digital images were acquired every 5 s (50–100ms exposures
for ∼100 × 200 pixel sub-arrays, 1 × 1 binning) for a total time
of 10min. The position of fluorescent puncta was tracked as a
function of time using the Particle Tracking module of Imaris
(Bitplane).
DRUG TREATMENTS AND CELL VIABILITY ASSAYS
BDNF-YFP-transfected neurons were treated with the HDAC6
inhibitor Tubastatin A (1μM, prepared in 0.01% DMSO vehi-
cle) for 48 h; 0.01% DMSO was used as control. Cell viability was
assessed by trypan blue exclusion. Cells were rinsed with HBSS,
and incubated with 0.4% trypan blue solution (Gibco) for 2min
at room temperature. After washing with HBSS, dead and live
cells were counted in ten random fields per coverslip.
SURFACE STAINING OF BDNF-YFP IMMUNOFLUORESCENCE
The procedure for BDNF-YFP immunostaining on the surface
of cultured neurons was as described (Sadakata et al., 2012).
Twenty-four hours after BDNF-YFP transfection, cultured neu-
rons were stimulated with 50mM KCl for 10min in the absence
or presence of the voltage-gated Ca2+ channel blocker nifedipine
(50μM), the ionotropic glutamate receptor antagonists CNQX
(10μM) and D-APV (50μM), the GABAAR antagonist bicu-
culline (10μM), or the voltage-gated Na+ channel blocker TTX
(0.5μM), fixed with 4% (wt/vol) paraformaldehyde/sucrose for
5min, and then washed with PBS. After blocking with 10%
(vol/vol) goat serum in PBS, cells were incubated with anti-
GFP antibody (which also recognized YFP; Abcam) overnight at
4◦C, rinsed in PBS, and incubated with anti-rabbit secondary
antibody conjugated to Cy3 (Millipore) for 1 h; coverslips were
then mounted with Vectashield medium (Vector Laboratories).
Images were acquired in a laser-scanning confocal microscope
using a solid-state 488 nm laser for YFP excitation, a 543 nm
HeNe green laser for Cy3 excitation, a 60 × 1.4NA oil immer-
sion lens, and standard FITC and TRITC dichroic and emission
filters (FluoView-300, Olympus). Quantification of co-localized
pixels was performed using Colocalization module in Imaris. The
ratio of surface-bound BDNF-YFP to total BDNF-YFP was esti-
mated as volumetric percentage of co-localized signals over the
threshold.
WESTERN IMMUNOBLOTTING
For biochemical measurements of the levels of acetylated and
total α-tubulin, total cell lysates were obtained by rinsing 4 × 105
treated hippocampal neurons with cold PBS followed by lysis
in NP-40 lysis buffer (20mM Tris at pH 8.0, 137mM NaCl,
10% glycerol, 1% Nonidet P-40, 2mM EDTA) containing pro-
tease inhibitor. The cell lysates were maintained with constant
agitation for 30min at 4◦C and centrifuged at 12,000 g for
20min. The supernatants were aspirated and protein concen-
trations were quantified by the Lowry method. Fifteen micro-
grams of total lysate were subjected to SDS-PAGE (Bio-Rad)
and Western blot analysis with primary antibodies against acety-
lated α-tubulin (1:1000; Sigma) and total α-tubulin (1:2000; Life
Technologies). Immunodetection was performed using Odyssey
infrared imaging system (Li-Cor Bioscience).
STATISTICAL ANALYSES
All the experiments were performed at least 3 different times,
from at least 3 different neuronal culture preparations. Data are
presented as mean± standard error of the mean (SEM), and were
compared using unpaired Student’s t-test for two groups or One
Way ANOVA with Tukey post test for more than three groups;
percentages were compared using Chi-square test. All analyses
were performed using Prism software (GraphPad Software, San
Diego, CA). P < 0.05 was considered significant.
RESULTS
BDNF-YFP TRAFFICKING IS IMPAIRED INMECP2 KNOCKOUTNEURONS
The cellular localization, processing and secretion of exoge-
nously expressed BDNF-xFP have been reported to be identical to
those of endogenous native BDNF, including its co-localization
to secretory granule cargoes like chromogranin-B and SGA2
(Haubensak et al., 1998; Kohara et al., 2001; Lessmann and
Brigadski, 2009; Hartmann et al., 2012) (Supplemental Figure 1).
To evaluate whether the dynamics of dendritic BDNF traf-
ficking is altered by Mecp2 deletion, time-lapse fluorescence
imaging of BDNF-YFP was performed in primary cultures of
hippocampal neurons (12–14 days in vitro, DIV) from male
Mecp2 knockouts and wildtype littermates. BDNF-YFP puncta
are widely distributed and move bi-directionally in live neu-
rons (Figures 1A,B), as previously described (Park et al., 2008;
Matsuda et al., 2009). The average velocity of BDNF-YFP puncta
was significantly slower in Mecp2 knockout neurons (0.10 ±
0.01μm/s, n = 261 puncta from 8 cells) compared to wildtype
cells (WT 0.25 ± 0.01μm/s, n = 225 puncta from 8 cells; p <
0.001). Analyses of the distributions of the velocity of BDNF-YFP
puncta revealed that the number of fast moving puncta (veloc-
ity>0.4μm/s) is significantly smaller inMecp2 knockout neurons
(Mecp2 1.30 % vs. WT 16.77 %; p < 0.001; Figures 1C,D). To
quantify BDNF transport efficiency, we compared the persistence
of each BDNF-YFP puncta, estimated as the ratio of total distance
traveled during an image sequence over the minimum displace-
ment between image frames (Gauthier et al., 2004). Consistent
with impaired and slower BDNF trafficking, the persistence
of BDNF-YFP puncta was higher in Mecp2 knockout neurons
(Mecp2 7.14 ± 0.98 vs. WT 3.91 ± 0.43; p < 0.05; Figure 1E).
Then, we tested whether the transport of other organelles such
as mitochondria is also affected by Mecp2 deletion. Intriguingly,
time-lapse imaging of MitoTracker-Red puncta revealed a lower
percentage of fast moving mitochondria in Mecp2 knockout neu-
rons (Mecp2 6.08 % vs. WT 12.39 %; p < 0.01; Figure 1F),
but no significant differences in their average velocity or persis-
tence between Mecp2 knockout (n = 410 puncta from 13 cells)
and wildtype neurons (n = 359 puncta from 14 cells; p > 0.05;
Figures 1G,H).
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FIGURE 1 | BDNF-YFP trafficking is impaired in Mecp2 knockout
neurons. (A) Representative example of a cultured pyramidal neuron
expressing BDNF-YFP; scale bar = 10μm. The white square is enlarged in
(B). (B) Movement of BDNF-YFP punta (a, b, and c); scale bar = 5μm. Each
image was taken at the time point indicated at bottom left. (C) Distributions
of velocities of BDNF-YFP puncta in wildtype and Mecp2 knockout neurons.
(D) Cumulative frequency of velocities of BDNF-YFP puncta from the
histograms shown in (C). (E) Cumulative frequency of persistence of
BDNF-YFP puncta. (F) Distributions of velocities of MitoTracker-Red puncta in
wildtype and Mecp2 knockout neurons. (G) Cumulative frequency of
velocities of MitoTracker-Red puncta from the histograms shown in (F).
(H) Cumulative frequency of persistence of MitoTracker-Red puncta.
THE IMPAIRMENT OF BDNF-YFP TRAFFICKING INMECP2 KNOCKOUT
NEURONS IS BI-DIRECTIONAL
Anterograde BDNF transport from somata to dendrites and axon
terminals is important for activity-dependent BDNF release to
participate in synaptic plasticity, while retrograde BDNF trans-
port back to the soma is critical for neurotrophin recycling and
nuclear signaling (Egan et al., 2003; Park et al., 2008). When
BDNF-YFP puncta were separated by their trafficking direc-
tion, Mecp2 knockout neurons showed significantly fewer BDNF
puncta moving in both anterograde and retrograde directions
than wildtype neurons, with a significantly shorter total distance
traveled in either direction in Mecp2 knockout cells (p < 0.001;
Figures 2A,B). Consistently, the average velocity of BDNF-YFP
punctamoving in both anterograde and retrograde directions was
significantly slower (p < 0.001; Figure 2C), and their persistence
higher (p < 0.05 in retrograde direction; Figure 2D), in Mecp2
knockout neurons.
THE HDAC6-SELECTIVE INHIBITOR TBA IMPROVES BI-DIRECTIONAL
BDNF-YFP TRAFFICKING INMECP2 KNOCKOUT NEURONS
HDAC6 removes acetyl groups from α-tubulin (Hubbert et al.,
2002; Matsuyama et al., 2002; Zhang et al., 2003), which
makes microtubules less stable. Since BDNF is transported
along microtubules (Gauthier et al., 2004), inhibiting HDAC6
is expected to improve BDNF trafficking by stabilizing micro-
tubules (Dompierre et al., 2007). We tested whether treatment
with the selective HDAC6 inhibitor enhances BDNF-YFP traffick-
ing in cultured hippocampal neurons. Treatment with Tubastatin
A for 48 h (TBA, 1μM, prepared in 0.01% DMSO) was not
neurotoxic, as determined by trypan blue exclusion (p > 0.05;
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FIGURE 2 | Bi-directional BDNF-YFP trafficking is impaired in Mecp2
knockout neurons. (A) Proportion of BDNF-YFP puncta that moves in
the anterograde or retrograde directions, flutter within a small distance
(10μm) or not moving at all in wildtype and Mecp2 knockout neurons.
(B) Scatter plots showing analyses of movement of BDNF-YFP puncta in
anterograde and retrograde directions. (C) Average velocity of BDNF-YFP
puncta was significantly slower in Mecp2 knockout neurons for both
directions. (D) Persistence of BDNF-YFP puncta was also higher in
Mecp2 knockout neurons for both directions. ∗∗∗p < 0.001 wildtype vs.
Mecp2 knockout.
Supplemental Figure 2A). Then, we confirmed that TBA affected
the acetylation state of α-tubulin under our experimental con-
ditions. Western immunoblots of cultured hippocampal neurons
(DIV12) treated with TBA showed that the levels of acetylated
tubulin were significantly increased in wildtype neurons (p <
0.01; Supplemental Figure 2B), and elevated by two times in
Mecp2 knockout neurons (p < 0.001; Supplemental Figure 2B).
Next, we tested the effect of HDAC6 inhibition on BDNF-YFP
trafficking. Compared to vehicle-treated neurons (162 puncta
from 7 cells), TBA increased the proportion of retrogradely mov-
ing BDNF puncta (159 puncta from 7 cells; p < 0.01; Figure 3A),
as well as the average velocity of punctamoving anterogradely and
retrogradely in Mecp2 knockout neurons (p < 0.001; Figure 3B).
However, TBA did not affect the persistence of BDNF puncta in
Mecp2 knockout neurons (p > 0.05; Figure 3C). On the other
hand, TBA had no effect in any of these BDNF-YFP trafficking
parameters in wildtype neurons (DMSO 106 puncta from 5 cells;
TBA 149 puncta from 7 cells; p > 0.05; Figures 3A–C).
ACTIVITY-DEPENDENT BDNF RELEASE WAS IMPAIRED INMECP2
KNOCKOUT NEURONS, AND IMPROVED BY INHIBITING HDAC6
Improving BDNF transport to release sites could in principle
also enhance its activity-dependent release. To estimate activity-
dependent BDNF secretion, BDNF-YFP-expressing neurons were
depolarized with 50mM KCl, followed by immunostaining with
anti-YFP antibody before cell permeabilization. The degree of
co-colocalization between immunopositive puncta (labeled with
red-conjugated anti-YFP secondary antibody), and native YFP
fluorescent puncta after fixation is directly proportional to
BDNF-YFP secreted during neuronal depolarization (Figure 4A),
as described (Sadakata et al., 2012). KCl-induced postsynap-
tic secretion of BDNF depends on Ca2+ influx (Hartmann
et al., 2001; Kolarow et al., 2007), mainly through L-type
voltage-gated Ca2+ channels (Wang et al., 2002). Here, we con-
firmed that elevated KCl-induced BDNF secretion was absent
in a Ca2+ free solution (n = 18 cells), or in the presence
of the L-type Ca2+channel blocker nifedipine (50μM; n =
16; p < 0.05; Figure 4B). Ca2+ channels can also be activated
by depolarization from GABAA receptor activity in immature
neurons with high intracellular Cl− concentration (Fiorentino
et al., 2009; Porcher et al., 2011). Indeed, the GABAA recep-
tor antagonist bicuculline also prevented KCl-induced BDNF
secretion (10μM; n = 15; p < 0.05; Figure 4B). In addition,
KCl-induced BDNF secretion required functional ionotropic glu-
tamate receptor activity (10μM CNQX, 50μM D-APV; n = 17;
p < 0.01), and voltage-sensitive Na+ channels (0.5μM TTX;
n = 19; p < 0.05; Figure 4B), as previously described (Lessmann
et al., 2003). Figure 5 illustrates the different mechanisms
leading to Ca2+-dependent BDNF release during KCl-induced
depolarization.
Consistent with reports of impaired activity-dependent
BDNF release using different assays (Li et al., 2012), the
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FIGURE 3 | TBA improves BDNF-YFP trafficking in Mecp2 knockout
neurons. (A) Proportion of BDNF-YFP puncta that moves in anterograde or
retrograde directions, flutter or not move in wildtype and Mecp2 knockout
neurons, with or without TBA. (B) TBA increased the average velocity of
both anterograde and retrograde BDNF-YFP puncta only in Mecp2 knockout
neurons. (C) TBA did not affect BDNF puncta persistence in neither
wildtype nor Mecp2 knockout neurons. ∗∗p < 0.01; ∗∗∗p < 0.001 wildtype
vs. Mecp2 knockout.
proportion of BDNF secreted during KCl-induced depolar-
ization was significantly smaller in Mecp2 knockout neu-
rons (n = 21) than in wildtype neurons (n = 25; p < 0.01;
Figure 4B). In addition, there was no evidence of BDNF secre-
tion in Mecp2 knockout neurons under any of the condi-
tions of activity blockade described above (Ca2+ free n =
15; nifedipine n = 13; CNQX/D-APV n = 16; bicuculline n =
15; TTX n = 13; p > 0.05; Figure 4B). Intriguingly, TBA sig-
nificantly improved the proportion of BDNF secreted dur-
ing KCl-induced depolarization in Mecp2 knockout neurons
(n = 14; p < 0.001; Figure 4B), but not in wildtype neu-
rons (n = 22; p > 0.05; Figure 4B). These results suggest that
improved microtubule-dependent trafficking allowed a larger
pool of BDNF to be transported to release sites and be avail-
able for activity-dependent release, underscoring the potential
therapeutic benefit of this approach to restore BDNF signal-
ing in RTT.
DISCUSSION
Dysfunctional BDNF signaling likely contributes to several patho-
physiological mechanisms of RTT. Previous studies have reported
lower BDNF mRNA and protein levels in Mecp2-deficient mice
and RTT individuals (Chang et al., 2006; Wang et al., 2006;
Abuhatzira et al., 2007). Also, axonal transport of BDNF is altered
when Mecp2 levels are modified in cultured cortical neurons
(Roux et al., 2012). Here, we demonstrate impaired bi-directional
trafficking of BDNF in hippocampal neurons fromMecp2 knock-
out mice. Since anterograde BDNF trafficking likely reflects deliv-
ery to release sites, while retrograde BDNF trafficking represents
signaling endosomes directed to the cell nucleus (Egan et al.,
2003; Park et al., 2008), our results suggest that both activity-
dependent BDNF release, as well as neurotrophin recycling and
nuclear signaling are affected in MeCP2-deficient neurons. Using
a novel assay of BDNF secretion based on surface immunostanin-
ing of BDNF-YFP in live neurons after neuronal depolarization
(Sadakata et al., 2012), we confirmed that activity-dependent
BDNF release is impaired in hippocampal neurons from Mecp2
knockout mice (Li et al., 2012). Since microtubules containing
acetylated α-tubulin aremore stable, and BDNF vesicles are trans-
ported along microtubules (Gauthier et al., 2004), we confirmed
that selective inhibition of cytoplasmic HDAC6—which increases
acetylated α-tubulin levels—improves not only BDNF traffick-
ing, but also its activity-dependent secretion. Taken together,
our findings suggest that, in addition to BDNF mRNA and pro-
tein levels, dysfunctional BDNF trafficking and release contribute
to RTT neuropathology. Thus, targeting the molecular machin-
ery responsible for BDNF trafficking and release represents a
novel strategy to reverse BDNF-dependent neurological deficits
in RTT.
Is this impairment in trafficking specific for BDNF-containing
vesicles, or does it affect other cellular elements transported along
microtubules?Mecp2 deficiency impairs axonal transport of amy-
loid precursor protein (App) without affecting its mRNA and
protein levels (Roux et al., 2012). Also, we showed here that
Mecp2 knockout neurons have fewer fast-moving mitochondria
than wildtype neurons, suggesting that MeCP2 deficiency affects
microtubule-dependent transport in general. Whether and how
the molecular motors responsible for anterograde (kinesin-1),
and retrograde transport (dynein/dynactin) are affected in RTT
needs to be further explored.
We showed that the selective HDAC6 inhibitor TBA improves
BDNF trafficking in Mecp2 knockout neurons by increasing the
proportion of moving BDNF puncta and their average veloc-
ity in both anterograde and retrograde directions. TBA also
restored activity-dependent BDNF release in Mecp2 knockout
neurons to levels comparable to those of wildtype neurons.
How did HDAC6 inhibition produce these effects? It is known
that acetylation of α-tubulin at Lys-40 promotes axonal trans-
port of cargo proteins by increasing microtubule stability (Reed
et al., 2006; Bulinski, 2007), and that inhibition of HDAC6 is
responsible for such increased α-tubulin acetylation that leads
to enhanced axonal transport of lysosomes and other secretory
vesicles (Dompierre et al., 2007). Consistently, in vivo treatment
with TBA improves axonal trafficking in a mouse model of
Charcot-MarieTooth disease by increasing α-tubulin acetylation
and enhancing microtubule rigidity (d’Ydewalle et al., 2011).
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FIGURE 4 | Activity-dependent release of BDNF-YFP is impaired in
Mecp2 knockout neurons. (A) Representative examples of BDNF
release in wildtype and Mecp2 knockout neurons: no treatment,
stimulated with KCl, stimulated with KCl in the absence of extracellular
Ca2+ and stimulated with KCl upon TBA treatment; scale bar = 10μm.
BDNF-YFP is shown in green, while YFP immunoreactivity is shown in
red. Yellow pixels represent colocalization of green and red pixels, i.e.,
secreted BDNF. (B) Proportion of released BDNF per total BDNF upon
KCl stimulation in wildtype neurons and Mecp2 knockout neurons in the
absence or presence of extracellular Ca2+, nifedipine (50μM), CNQX
(10μM) /D-APV (50μM), Bicuculline (10μM), TTX (0.5μM) or TBA (1μM).
The proportion of released BDNF per total BDNF was normalized to that
in non-stimulated neurons (Ctl), and expressed as % of Ctl. ∗∗p < 0.01;
wildtype vs. Mecp2 knockout; ∗∗∗p < 0.001 compared to Mecp2 knockout
Ctl group stimulated with KCl; #p < 0.05; ##p < 0.01 compared to
wildtype Ctl group stimulated with KCl.
Therefore, HDAC6 inhibitors represent a potential therapeutic
strategy for neurodegenerative disorders in which microtubule-
dependent intracellular transport is impaired (Dompierre et al.,
2007; Kim et al., 2012). Our results also showed that TBA
increased α-tubulin acetylation in wildtype neurons, but not as
much as in Mecp2 knockout neurons. However, we didn’t find
any effect of TBA in wildtype neurons. This might be because
BDNF trafficking is in the optimal state in wildtype neurons. TBA
restored impaired BDNF trafficking in Mecp2 knockout neurons
to wildtype levels.
In the present study with BDNF-YFP transfected in hip-
pocampal neurons, we cannot exclude an artifact of BDNF
overexpression to endogenous levels. However, the intracellular
localization of BDNF-YFP is similar to that of endoge-
nous BDNF, including its co-localization to secretory granule
cargoes like chromogranin-B and SGA2 (Haubensak et al.,
1998; Kohara et al., 2001; Lessmann and Brigadski, 2009;
Hartmann et al., 2012) (Supplemental Figure 1), suggesting that
the trafficking properties of BDNF-YFP can be comparable
to those of endogenous BDNF. Even though BDNF expres-
sion is higher, we cannot ignore the differences of BDNF
trafficking and release between wildtype and Mecp2 knockout
neurons.
In conclusion, our findings revealed that bi-directional
trafficking of BDNF and its activity-dependent release are
significantly impaired in hippocampal neurons of Mecp2
knockout mice, and that this deficit can be improved by
enhancing tubulin acetylation with a selective HDAC6 inhibitor,
which should improve microtubule-based transport. Targeting
molecular components responsible for microtubule-based
trafficking of BDNF-containing dense core vesicles is a potential
strategy to reverse cellular and synaptic impairments in RTT.
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FIGURE 5 | Mechanisms of Ca2+-dependent BDNF release during
KCl-induced depolarization. KCl-induced BDNF secretion depends on
Ca2+ influx, which can be mediated by L type-VGCC, AMPA
receptors, NMDA receptors, GABAA receptors and voltage-sensitive
Na+ channels.
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Supplemental Figure 1| Distribution of exogenously expressed BDNF-YFP
is comparable to that of endogenous native BDNF. (A) Representative
example of a cultured hippocampal pyramidal neuron after dual
immunostaining for endogenously expressed native BDNF (red) with
chromogranin-B (green), a marker of secretory granules. The inset shows
colocalization in a dendritic segment. (B) Immunostaining for
chromogranin-B (red) on a BDNF-YFP-expressing neuron (green) reveals
essentially the same patter of colocalization. (C,D) The same pattern of
co-localization between exogenous BDNF-YFP and endogenous BDNF is
observed in cultured hippocampal pyramidal neurons from either WT (C)
mice or Mecp2 knockout mice (D). Scale bar = 10μm.
Supplemental Figure 2| TBA increases tubulin acetylation. (A) Cell viability
assessed by trypan blue exclusion. (B) Extracts from DIV12 wildtype cells
and Mecp2 knockout neurons treated with or without TBA (1μM) for 48 h
were processed by Western blot and analyzed for acetylated tubulin and
total tubulin. GAPDH was performed as loading control (top).
Quantification of protein levels for acetylated tubulin in each group (n = 4)
was normalized to that in wildtype neurons (WT) and expressed as % of
WT. ∗p < 0.05; ∗∗p < 0.01 compared to WT group; ∗∗∗p < 0.001 compared
to Mecp2 knockout group (bottom).
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